Repositorio de producción científica de la Universidad de Sevilla

Final results of the telaprevir access program: Fibroscan values predict safety and efficacy in hepatitis c patients with advanced fibrosis or cirrhosis

Opened Access Final results of the telaprevir access program: Fibroscan values predict safety and efficacy in hepatitis c patients with advanced fibrosis or cirrhosis

Citas

buscar en

Estadísticas
Icon
Exportar a
Autor: Lepida, Antonia
Colombo, Massimo
Abdurakhmanov, Djamal
Ferreira, Paulo Abrao
Strasser, Simone I.
Urbanek, Petr
Mangia, Alessandra
Calleja, José L.
Iraqi, Wafae
DeMasi, Ralph
Lonjon-Domanec, Isabelle
Moreno, Christophe
Wedemeyer, Heiner
Departamento: Universidad de Sevilla. Departamento de Química Orgánica y Farmacéutica
Fecha: 2015
Publicado en: PLoS One, 10 (9), e0138503-.
Tipo de documento: Artículo
Resumen: Background: Liver stiffness determined by transient elastography is correlated with hepatic fibrosis stage and has high accuracy for detecting severe fibrosis and cirrhosis in chronic hepatitis C patients. We evaluated the clinical value of baseline FibroScan values for the prediction of safety and efficacy of telaprevir-based therapy in patients with advanced fibrosis and cirrhosis in the telaprevir Early Access Program HEP3002. Methods: 1,772 patients with HCV-1 and bridging fibrosis or cirrhosis were treated with telaprevir plus pegylated interferon-α and ribavirin (PR) for 12 weeks followed by PR alone, the total treatment duration depending on virological response and previous response type. Liver fibrosis stage was determined either by liver biopsy or by non-invasive markers. 1,282 patients (72%) had disease stage assessed by FibroScan; among those 46% were classified as Metavir F3 at baseline and 54% as F4. Results: Overall, 1,139 patients (64%) achieved a sustained virological...
[Ver más]
Cita: Lepida, A., Colombo, M., Fernández Fernández, I., Abdurakhmanov, D., Ferreira, P.A., Strasser, S.I.,...,Wedemeyer, H. (2015). Final results of the telaprevir access program: Fibroscan values predict safety and efficacy in hepatitis c patients with advanced fibrosis or cirrhosis. PLoS One, 10 (9), e0138503-.
Tamaño: 330.6Kb
Formato: PDF

URI: http://hdl.handle.net/11441/42513

DOI: http://dx.doi.org/ 10.1371/journal.pone.0138503

Mostrar el registro completo del ítem


Esta obra está bajo una Licencia Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internacional

Este registro aparece en las siguientes colecciones